Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 22;8(2):304.
doi: 10.3390/microorganisms8020304.

Daily Intake of Paraprobiotic Lactobacillus amylovorus CP1563 Improves Pre-Obese Conditions and Affects the Gut Microbial Community in Healthy Pre-Obese Subjects: A Double-Blind, Randomized, Placebo-Controlled Study

Tomonori Sugawara  1 , Daisuke Sawada  1 , Sae Yanagihara  1 , Yumeko Aoki  1 , Isao Takehara  2 , Hirosuke Sugahara  1 , Tatsuhiko Hirota  1 , Yasunori Nakamura  1 , Susumu Ishikawa  3
Affiliations

Daily Intake of Paraprobiotic Lactobacillus amylovorus CP1563 Improves Pre-Obese Conditions and Affects the Gut Microbial Community in Healthy Pre-Obese Subjects: A Double-Blind, Randomized, Placebo-Controlled Study

Tomonori Sugawara et al. Microorganisms. .

Abstract

Despite the fact that gut microbiota is closely associated with obesity, few studies have focused on the influences of paraprobiotics as food ingredients on both obesity prevention and the gut microbial community. In this study, we evaluated the effects of fragmented Lactobacillus amylovorus CP1563 (CP1563) as a paraprobiotic for obesity prevention and investigated its effects on the gut microbial community in pre-obese subjects. One hundred sixty-nine healthy subjects with a body mass index from 25.0 to 29.9 kg/m2 ingested beverages with or without the fragmented CP1563 containing 10-hydroxyoctadecanoic acid (10-HOA) for 12 weeks. The changes in abdominal, total, visceral, and subcutaneous fatty areas were significantly lower in the CP1563-10-HOA group than in the placebo group at 12 weeks. Furthermore, 16S rRNA gene sequencing of fecal DNA revealed that the changes in the abundances of the genera Roseburia and Lachnospiraceae;g were significantly greater in the CP1563-10-HOA group than in the placebo group, and the changes in the abundances of the genus Collinsella was significantly smaller in the CP1563-10HOA group than in the placebo group. Our results showed that continuous ingestion of the fragmented CP1563 containing 10-HOA reduced abdominal body fat and affected the gut microbial community in pre-obese healthy subjects. Our findings may contribute to the understanding of the relationship between the anti-obesity effect of paraprobiotics and gut microbiota.

Keywords: 10-hydroxyoctadecanoic acid; Lactobacillus amylovorus CP1563; butyrate-producing bacteria; clinical trial; gut microbiota; obesity; paraprobiotics.

PubMed Disclaimer

Conflict of interest statement

T.S., D.S., S.Y., Y.A., H.S., T.H., and Y.N. are employees of Asahi Quality and Innovations, Ltd., which is related to Asahi Group Holdings, Ltd. The other authors declare that the research was conducted in the absence of any financial relationships that could be constructed as potential conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of the progress stages of this study.
Figure 2
Figure 2
Changes in abdominal fat areas. Changes in total fat area (a), changes in visceral fat area (b), and changes in subcutaneous fat area (c). Data are shown as the mean ± SEM (the CP1563-10-HOA group: n = 85, the placebo group: n = 84). * p < 0.05, ** p < 0.01. vs. placebo group (by Student’s t-test). # p < 0.05, ## p < 0.01. vs. baseline (by Dunnett’s test).
Figure 3
Figure 3
Changes in anthropometric parameters. Changes in body weight (a) and changes in BMI (b). Data are shown as the mean ± SEM (the CP1563-10-HOA group: n = 85, the placebo group: n = 84). ** p < 0.01. vs. placebo group (by Student’s t-test.). ## p < 0.01. vs. 0 weeks (by Dunnett’s test).
Figure 4
Figure 4
Plots of the placebo and CP1563-10-HOA groups at 0 (a) and 12 (b) weeks were visualized by principal coordinate analysis (PCoA) based on the Bray–Curtis distance using the bacterial taxa at the genus level (the CP1563-10-HOA group at 0 weeks: n = 83, at 12 weeks: n = 82; the placebo group at 0 weeks: n = 84, at 12 weeks: n = 83). The p values were calculated by permutational MANOVA based on the Bray–Curtis distance using the bacterial taxa at the genus level.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mathieu P., Pibarot P., Despres J.P. Metabolic syndrome: The danger signal in atherosclerosis. Vasc. Health Risk Manag. 2006;2:285–302. doi: 10.2147/vhrm.2006.2.3.285. - DOI - PMC - PubMed
    1. Sharma A.M., Chetty V.T. Obesity, hypertension and insulin resistance. Acta Diabetol. 2005;42:S3–S8. doi: 10.1007/s00592-005-0175-1. - DOI - PubMed
    1. Simopoulos A.P. Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease. Nutrients. 2013;5:2901–2923. doi: 10.3390/nu5082901. - DOI - PMC - PubMed
    1. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.-Y., Keilbaugh S.A., Bewtra M., Knights D., Walters W.A., Knight R., et al. Linking long-term dietary patterns with gut microbial enterotypes. Sciences. 2011;334:105–108. doi: 10.1126/science.1208344. - DOI - PMC - PubMed
    1. Shen T.D. Diet and Gut Microbiota in Health and Disease. Nestle Nutr. Inst. Workshop Ser. 2017;88:117–126. doi: 10.1159/000455220. - DOI - PubMed

LinkOut - more resources